In adults with type 2 diabetes, tirzepatide significantly decreased the visceral adipose tissue z-score from baseline to week 52.
In plain wordsIn adults with type 2 diabetes, tirzepatide lowered belly (visceral) fat relative to matched controls over 52 weeks.
- Peptide
- Tirzepatide
- Outcome
- DecreaseVisceral adipose tissue z-score change at week 52
- Study
n: not reported in source
- Comparator
- Sex- and BMI-matched virtual control groups
- Analysis
- Exploratory
- Outcome group
- Body composition · Metabolic and weight
- Studied dose
- 5, 10 and 15 mg · 52 weeksAs given in this study (human).
Measurements
- z-VAT change
- −0.18 z-score
- tirzepatide, baseline to week 52
Source sentences
Tirzepatide-treated participants had significant decreases in z-VAT (-0.18 [0.58]; p < 0.001) and z-LF (-0.54 [0.84]; p < 0.001) but increased z-aSAT (+0.11 [0.50]; p = 0.012).
2 context sentences(design, population, supporting numbers)
To describe the overall fat distribution patterns independent of body mass index (BMI) in participants with type 2 diabetes (T2D) in the SURPASS-3 MRI substudy by comparison with sex- and BMI-matched virtual control groups (VCGs) derived from the UK Biobank imaging study at baseline and Week 52.
For each study participant at baseline and Week 52 (N = 296), a VCG of ≥150 participants with the same sex and similar BMI was identified from the UK Biobank imaging study (N = 40 172).